Brain ¿ from Development to Neoplasia, and Gene Therapy Solution - Trojan, Jerzy
46,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
23 °P sammeln
  • Broschiertes Buch

Differentiation of nervous tissue, which occurs during CNS development, was first described in detail while investigating a model of rat brain through the use of a new biomarker known as alpha-fetoprotein, AFP. During this research, another model -mouse teratocarcinoma - enabled the description of the different steps of nervous tissue formation following distinct pathological ways of CNS development. Comparing these two processes gave rise to the following conclusions: a striking convergence exists between normal and neoplastic nervous tissue development and correlates with the presence of…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Differentiation of nervous tissue, which occurs during CNS development, was first described in detail while investigating a model of rat brain through the use of a new biomarker known as alpha-fetoprotein, AFP. During this research, another model -mouse teratocarcinoma - enabled the description of the different steps of nervous tissue formation following distinct pathological ways of CNS development. Comparing these two processes gave rise to the following conclusions: a striking convergence exists between normal and neoplastic nervous tissue development and correlates with the presence of oncoproteins such as AFP and growth factor IGF-I. These interesting observations have oriented the pursuit of one goal: stopping the neoplastic CNS development conducing to the malignant tumor - glioblastoma. From this endeavor, stemmed an efficient anti-gene strategy targeting gene of growth factor IGF-I present in brain tumor development, inducing immune anti-tumor response and consequently, increasing the median survival of glioblastoma patients up to 2 years.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Jerzy Trojan has completed his Habilitation (Doctorat d¿Etat es Sciences) in 1981 in Paris VI University, and joined in 1984 INSERM. He is a co-author of 218 publications (Research Gate profile 2017). Between 1993-2017 he has established cancer immunogene therapy as a new oncology domain (Trojan et al, Science 1993; Wikipedia, Gene therapy, 2017)